• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Freenome (FRNM) Following FDA Approval Why Its 36.8x P S Still Looks Pricey

    Simply Wall St·08/10/2026 03:33:03
    语音播报

    Freenome (FRNM) stock is in focus after the company and Abbott received U.S. Food and Drug Administration approval for SimpleScreen CRC, a blood based colorectal cancer screening test for average risk adults.

    See our latest analysis for Freenome.

    The FDA approval and upcoming U.S. launch of SimpleScreen CRC comes as Freenome trades at US$11.15, with a 30 day share price return of 3.24% and a year to date share price decline of 14.23%. The 1 year total shareholder return is 5.49%, suggesting recent momentum has picked up from a weaker stretch earlier in the year.

    If this kind of healthcare AI breakthrough has your attention, it could be a good moment to scan the wider space through our screener of 43 healthcare AI stocks

    After the FDA approval news and recent share price rebound, the gap between Freenome’s current US$11.15 level and where different fair value estimates cluster is what really matters next. How wide is that spread in today’s numbers?

    Preferred Price-to-Sales Multiple of 36.8x: Is It Justified?

    Freenome currently trades on a P/S ratio of 36.8x, while also sitting below its 1 year industry and market returns, so the key question is whether that premium can be explained by the current fundamentals.

    The P/S multiple compares Freenome’s share price to its revenue per share. For early stage biotech companies that are still loss making, investors often look at P/S because earnings are negative and P/E is not meaningful. A higher P/S usually implies that the market is paying more today for each dollar of current revenue, often when investors are focused on the potential for future products and commercialisation rather than present profitability.

    Against that backdrop, Freenome’s 36.8x P/S ratio stands well above the US Biotechs industry average of 11.4x and a peer average of 13.1x. That is a sizeable premium. It suggests the market is currently pricing in expectations that differ from the broader group, even though there is insufficient forecast data to spell out what that might look like in future revenue or earnings terms.

    See what the numbers say about this price — find out in our valuation breakdown.

    Result: Price-to-Sales of 36.8x (OVERVALUED)

    However, investors in Freenome also need to watch execution risk around commercial uptake of SimpleScreen CRC, as well as the company’s ongoing losses of US$225.028 million.

    Find out about the key risks to this Freenome narrative.

    Next Steps

    With mixed signals around Freenome’s valuation and execution risks, it makes sense to look under the hood yourself and move quickly while sentiment is still forming. To get a clearer sense of the balance between potential upside and downside, take a close look at the 1 key reward and 2 important warning signs

    Looking For More Investment Ideas Beyond Freenome?

    If you want more context around Freenome, it helps to compare it with other stocks that have clear financial traits, strong balance sheets or income profiles.

    Do not leave it to chance. Spend a few minutes with these focused stock ideas so you avoid missing opportunities that fit your goals.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.